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Although obesity is a common co-morbid condition in COPD, relatively little is known how it
may affect functional exercise capacity. Accordingly, we compared physiologic responses
during a 6 min walk test in 10 obese and 10 non-obese COPD patients matched by gender,
age, and spirometric severity category. Patients first exercised on a treadmill to determine
maximal exercise responses, then following a rest period they completed a 6 min walk test.
Breath by-breath analyses of expired air via a facemask was obtained using a portable, battery
operated device. Oxygen consumption (VO2), carbon dioxide production (VCO2), tidal volume
(VT), respiratory rate (RR), minute ventilation (VE), and inspiratory capacity (IC) were
compared.
The mean FEV1 in the obese and non-obese groups was 52  13 and 58  18 percent of pre-
dicted, respectively, and the BMI of the obese patients was 37  02 kg/m2. Obese patients had
shorter 6 min walk distances than non-obese patients (247  73 vs 348  51 m, respectively,
pZ 0.003), but walk-work, defined as 6 min walk distance  weight (in kg), was not different.
There were no significant between-group differences in any exercise variable measured during
the 6 min walk test. In both groups, VO2 and VE increased linearly over the first 2e3 min, then
plateaued at approximately 80% of maximum. Although 6 min walk distance is shorter in obese
COPD patients, their physiologic responses are similar to those of non-obese patients.
ª 2011 Elsevier Ltd. All rights reserved.Hospital & Medical Center, Section of Pulmonary and Critical Care Medicine, Hartford, CT 06105,
tmail.com (M. Ehsan).
1 Elsevier Ltd. All rights reserved.
1190 J. Bautista et al.Introduction
Both chronic obstructive pulmonary disease (COPD) and
obesity are prevalent in the developed world. For example,
the pooled prevalence of physiologically-defined COPD in
adults was approximately 10% in a systematic review and
meta-analysis of data from 28 countries.1 Likewise, theWorld
HealthOrganizationpredicts that, by 2015, around 700million
adults will be obese; this represents at least 10% of the pro-
jected global population.2 Therefore it is to be expected that
these two conditions should frequently co-exist. Indeed, the
prevalence of obesity in a primary care population of patients
with COPD has been estimated to be about 18%,3 and
abdominal obesity has approximately twice the prevalence in
COPD patients participating in pulmonary rehabilitation.4
COPD is characterized by progressive expiratory flow limi-
tation, gas exchange abnormalities, and static and dynamic
hyperinflation.5 Additionally, systemic effects of the disease,
such as peripheral muscle deconditioning, are common.5
These primary respiratory and systemic abnormalities
contribute to the dyspnea, exercise intolerance, functional
status limitation, and impairment in health status in COPD.6e9
In obesity, increased adipose tissue around the thorax and
abdomen and in the visceral cavity places an additional load
on the chest wall, resulting in reduced resting lung volumes
suchas the functional residualcapacityandexpiratory reserve
volume.10,11 Although obesity has no direct effect on airway
caliber, the lowFRC increases the likelihoodofexpiratoryflow
limitation and airway closure, causing hypoxemia from
ventilation-perfusion mismatching.10 Respiratory muscle
weakness, as evidenced by reduced maximal inspiratory
pressures, may also be present in obesity.12 Dyspnea, the
cardinal symptom of COPD, is also common in obesity,13
probably related to the above-described respiratory physio-
logic abnormalities, increased work requirements with exer-
cise, and (possibly) the presence of co-morbid conditions.
Obese COPD patients have shorter 6 min walk distances
than non-obese patients, although their walk-work (the
product of walk distance in m and body weight in kg) is
similar.14 This suggests that their poorer lower extremity
exercise performance reflects the increased work burden of
obesity. The influence of obesity as a co-morbid condition
on dyspnea and exercise tolerance in COPD was studied by
Ora and associates. Physiologic responses during cycle
ergometry in 18 obese and 18 non-obese patients with COPD
were compared.15 They demonstrated that the lower lung
volumes associated with obesity ameliorated the static and
dynamic hyperinflation in COPD, resulting in less dyspnea
(at iso-ventilation) and increased oxygen uptake. The use
of a cycle ergometer in this setting, however, potentially
reduces the effects of the increased weight burden on
exercise performance. Accordingly, we designed this study
to evaluate exercise physiology and performance during
walking, a more natural form of exercise in COPD patients.
Methods
Subjects
The study was approved by our Institutional Review Board
and informed consent was obtained in all participants. Westudied 20 COPD patients: 10 obese class II-III patients as
categorized by the World Health Organization (BMI greater
than 35 kg/m2 16) and 10 matched non-obese (BMI less than
30 kg/m2 but greater than 21 kg/m2) patients. Underweight
patients were excluded to reduce the potentially con-
founding effects of nutritional depletion on exercise
outcomes. Other inclusion criteria included: 1) A clinical
diagnosis of COPD; 2) An FEV1/FVC < 0.70; 3) An FEV1> 30%
of predicted, 4) Clinical stability in the respiratory disease
for at least one month; 5) No perceived clinical contraindi-
cations to exercise testing; 6) The clinical expectation that
oxygen saturation by pulse oximetry will remain above 85%
during exercise testing. Patients requiring supplemental
oxygen and those with co-morbid conditions that would put
them at risk during exercise testing were excluded.
Subject matching
Obese and non-obese subjects were matched by age (5
years), gender, and Global Initiative for Obstructive Lung
Disease (GOLD)17 spirometric severity categories. GOLD
spirometric classification is as follows: mild, FEV1/FVC< 0.70
and FEV1  80% predicted; moderate, FEV1/FVC < 0.70 and
FEV1 < 80% and predicted and 50%; and severe, FEV1/
FVC < 0.70 and FEV1 < 50% predicted and 30%. GOLD very
severe (FEV1 30% predicted) were excluded since theywere
likely to oxygen-desaturate with exercise.
Study design
This was a non-blinded, parallel observational study
comparing physiologic responses during the 6 min walk test
in matched obese and non-obese COPD patients. Demo-
graphic data analyzed included gender, age, smoking
history, co-morbid conditions, medications, height, weight,
and body-mass index (kg/m2).
Pulmonary functions studies were obtained at baseline,
with measurements of forced expiratory volume in 1 second
(FEV1), forced vital capacity (FVC), diffusing capacity
(DLCO), and inspiratory capacity (IC). Pulmonary function
testing followed American Thoracic Society performance
criteria. Maximal voluntary ventilation was estimated by
multiplying the FEV1 by 35.18
Following pulmonary function testing, an incremental
cardiopulmonary exercise test was performed on a tread-
mill to a symptom-limited maximum. Treadmill testing was
performed to determine physiologic variables at maximal
exercise. Following a warm-up walk at 1 mph and zero
percent grade, treadmill speed was increased at 1 -min
intervals to the patient’s stated normal brisk walking pace.
After 1 min at this speed, the treadmill incline was
increased by 1% every minute until the symptom-limited
maximum. Twelve-lead ECG monitoring and oxygen satu-
ration by pulse oximetry were assessed continuously.
Breath-by-breath analysis of expired air was obtained using
the Oxycon Mobile (Viasys Healthcare GmbH, Hoechberg,
Germany). This is a portable, battery operated system
mounted on the body via a vest. Breath-by-breath data was
collected through a facemask and sent to the host
computer system via wireless transmission. Oxygen
consumption (VO2), carbon dioxide production (VCO2), tidal
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(VE) were measured. Predicted maximal heart rate was
determined by subtracting the patient’s age from 220.
Dyspnea and leg fatigue were rated at 1 -min intervals using
10-point category scales. IC measurements were obtained
at 2 min intervals using the portable metabolic device.
After at least a 30 min rest, 6 min walk testing was
performed. For this test, patients were instructed to walk
as far as possible up and down an unrestricted corridor for
6 min. Rest periods were allowed and standardized
encouragement was offered after each minute. Borg ratings
of dyspnea and leg fatigue were obtained at 1-min inter-
vals. A practice test was not given. A 12-lead ECG and
oxygen saturation were recorded continuously during
testing. Breath-by-breath analyses of expired air were also
recorded, expressed as 1-min averages. IC measurements
were recorded at 2-min intervals. Metabolic assessments
and IC determinations were obtained using the same Oxy-
con Mobile device used for incremental treadmill testing.
The physiologic variables during the 6 min walk test were
expressed as absolute values and as percents of their
respective values determined during the prior incremental
treadmill testing.
Data analysis
Data are expressed as means  standard deviations. Group
comparisons of demographic, pulmonary function, and
exercise variables were made using paired t-tests (SAS).19
When comparing oxygen consumption during the 6 min
walk testing, walk distance was added as covariate in
a general linear model. A p < 0.05 was considered
significant.
Results
Demographic and pulmonary function variables in the two
groups are given in Table 1. Each group consisted of 5 males
and 5 females. The mean weight of obese patients was
103  11 kg and 75  14 kg in non-obese patients. The mean
BMI of the obese group, 37  02 kg/m2, is consistent with
a class II obese categorization by the WHO.16 The mean ageTable 1 Demographic and pulmonary function variables at base
Obese COPD
Gender (MaleeFemale) 5/5
BMI (kg/m2) 37  02
Age (yrs) 64  10
FEV1/FVC 0.60  0.11
FEV1 (L) 1.40  0.36
FEV1 percent-predicted 52  13
FVC (L) 2.37  0.59
FVC percent-predicted 66  15
IC (L) 2.03  0.34
DLCO percent-predicted 57  08
Abbreviations: BMIZ body mass index; FEV1Z forced expiratory volu
DLCO Z diffusing capacity of the lung for carbon monoxide.and FEV1 percent-predicted were not significantly
different, reflecting our matching of the two groups by age
and GOLD spirometric category. In obese patients, the FVC
was significantly lower (2.37  0.59 vs 2.94  0.88 L,
respectively, p Z 0.02), and the DLCO tended to be lower
(57  8 vs 51  14 respectively, p Z 0.07) than non-obese
patients. Other pulmonary function variables were also not
significantly different between groups.
Six obese and 3 non-obese patients were taking oral
beta-blockers for hypertension. Groups were similar with
respect to inhaled steroid and long acting beta agonist use
(5 and 6 per group, respectively), and long-acting anti-
cholinergic (3 and 4, respectively).
Physiologic variables at maximal exercise during tread-
mill testing for the two groups are given in Table 2. In obese
patients, the primary symptom limiting exercise was dysp-
nea in 8 and fatigue in 2; in non-obese patients all had
dyspnea as the primary symptom. Obese patients tended to
have a lower maximal heart rate, expressed as a percent of
predicted, than non-obese patients: 70  07 vs 81  13%,
respectively, p Z 0.05. Peak VO2, expressed as mL/kg/min
was lower in obese than non-obese patients: 11.3  2.2 vs
14.2  3.4 mL/kg/min, respectively, p Z 0.03. Peak VO2,
expressed as L/min, on the other hand was similar in both
groups. Both obese and non-obese patients demonstrated
significant hyperinflation at maximal treadmill exercise as
determined by decreases in IC: 0.83  0.60 L (pZ 0.002)
and 0.63  0.83 L (pZ 0.04), respectively. The between-
group changes in IC were not significant (p Z 0.54). There
were no group differences in respiratory rate at peak
exercise.
The mean 6 min walk distance in obese patients was
significantly less than non-obese patients: 247  73 vs
348  51 m, respectively, p Z 0.003. However, walk work,
defined by the equation, 6 min walk distance  weight (in
kg), was not significantly different: 25721  9211 vs
26381  7202, respectively, p Z 0.85.
Physiologic variables measured at the end of the 6 min
walk test are given in Table 3. There were no significant
between-group differences in any exercise variable. VO2,
expressed as L/min, tended to be higher in obese than non-
obese subjects (0.91  0.30 vs 0.73  0.27, respectively,
p Z 0.29). Even after adjusting for the z100 m between-line.
Non-Obese COPD p
5/5 e
26  03 0.0001
66  09 0.16
0.56  0.08 0.37
1.65  0.51 0.08
58  18 0.23
2.94  0.88 0.02
78  20 0.08
2.13  0.61 0.70
51  14 0.07
me in 1 s; FVCZ forced vital capacity; ICZ inspiratory capacity;
Table 2 Peak exercise variables at treadmill exercise testing.
Obese COPD Non-Obese COPD P
HR (beats per minute) 108  11 124  20 0.08
HR (% max) 70  07 81  13 0.05
RR (breaths/min) 33  06 34  05 0.84
VO2 (L/min) 1.15  0.25 1.07  0.40 0.59
VO2 (mL/kg/min) 11.2  2.2 14.2  3.4 0.03
RER 0.88  0.07 0.92  0.09 0.37
VE (L/min) 30  08 32  13 0.58
VE/MVV 0.69  0.17 0.57  0,17 0.06
O2 saturation (nadir) 93  02 94  04 0.45
Abbreviations: HRZ heart rate; RRZ respiratory rate; VO2Z oxygen consumption; VEZminute ventilation; VE/MVVZ ratio of minute
ventilation to maximal voluntary ventilation; RER Z respiratory exchange ratio (VO/VCO2).
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remained non-significant (p Z 0.13). None of the patients
in either group reached a respiratory exchange ratio >1.0,
suggesting that none reached an anaerobic threshold.
VO2 measurements at the end of each minute during
the 6 min walk test are depicted in Fig. 1a and b. In both
groups, VO2 increased in a linear fashion during the first
2 min then appeared to plateau. The VO2, expressed as
L/min (Fig. 1a) tended to be higher in obese patients, but
differences were non-significant at all time points. VO2,
expressed as a percent of the maximal value achieved on
treadmill testing (Fig. 1b), was remarkably similar in both
groups, plateauing at approximately 80%. VE followed the
same general pattern as VO2, although the plateau
appeared at approximately the 3rd minute. There were no
significant between-group differences in VE at any time
point. IC, which was measured at baseline and minutes 2,
4, and 6, decreased in both groups by the 2-min obser-
vation, then appeared to plateau in both groups.
Between-group differences were not significant in this
variable.Table 3 Exercise variables at the end of 6 min walk testing.
Obese COP
HR (beats/min) 92  10
RR (breaths/min) 29  04
O2 saturation (nadir) 93  03
VO2, L/min 0.91  0.3
VO2, L/min (% treadmill max) 74  20
VO2, mL/kg/min) 8.8  2.5
VO2, mL/kg/min (% treadmill max) 82  31
Respiratory exchange ratio 0.81  0.0
VE, L/min 24  08
VE, L/min (% treadmill max) 84  37
VE/MVV (%) 49  12
IC, L 1.40  1.0
Dyspnea (1e10, 10 Z highest) 2.6  1.2
Leg fatigue (1e10, 10 Z highest) 1.6  1.3
Abbreviations: HRZ heart rate; RRZ respiratory rate; VO2Z oxygen
ventilation to maximal voluntary ventilation; IC Z inspiratory capaciDiscussion
Obesity is frequently present in COPD patients and may
affect their symptoms, functional status and prognosis.
Despite this, relatively few studies have assessed the effect
of this co-morbid condition on outcomes. Accordingly, we
compared physiologic variables measured during the 6 min
walk test in obese and non-obese COPD patients matched
by age, gender, and spirometric severity category.
The two groups (5 males, 5 females in each) were
reasonably matched with respect to age, FEV1, inspiratory
capacity and diffusing capacity. The lower FVC percent-
predicted in the obese patients probably represents
a restrictive abnormality associated with obesity. On
preliminary treadmill exercise testing, heart rates at peak
exercise were lower in obese than non-obese patients:
70  7 versus 81  13 percent of predicted maximal,
respectively. Some of this difference may have been due to
a higher frequency of beta blocker use in the obese
patients. Peak VO2, expressed in L/min, was similar in bothD Non-obese COPD p
102  21 0.25
26  07 0.36
94  03 0.54
1 0.76  0.27 0.29
73  16 0.80
10.2  2.9 0.28
77  34 0.80
4 0.81  0.04 0.84
22  08 0.69
75  29 0.61
42  19 0.29
1 1.56  0.80 0.11
2.3  1.6 0.72
2.0  1.9 0.63
consumption; VEZminute ventilation; VE/MVVZ ratio of minute
ty.
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Figure 1 a and b: Oxygen consumption (VO2) measured at
baseline (time zero) and at the end of each minute during the
6 min walk test in obese and non-obese COPD patients. Fig. 1a
shows VO2 expressed as L/minute, while Fig. 1b shows VO2
expressed as a percentage of the maximal value determined
during treadmill exercise testing. In both groups, VO2 increased
in an apparent linear fashion up to 2 min, and then plateaued.
Although VO2 in L/min tended to be higher in obese patients,
differences were not significant. Both groups plateaued at
approximately 80% of their maximum determined from tread-
mill testing.
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expressed as mL/kg/min.
The obese group walked approximately 100 m less on
their 6 min walk test than their non-obese counterparts.
This difference is similar to that observed in a retrospective
analysis of 114 COPD patients completing pulmonary reha-
bilitation at one center.14 In that study, COPD patients with
a BMI > 30 kg/m2, despite having a higher FEV1, had a 66 m
shorter walk distance. Interestingly, amount of work per-
formed during the walk test, as estimated by walk-work
(weight  walk distance), in both studies was nearly iden-
tical in obese and non-obese patients. Therefore, it
appears that the shorter distance covered by obese
patients was matched by increased load.
Despite the differences in distance, physiologic
responses during the 6 min walk test were remarkably
similar in both groups. VO2 and VE increased in a linear
fashion over the first 2e3 min of walking, then appeared to
plateau at approximately 75% of their maximal value that
was determined from incremental treadmill testing. The IC
dropped early and similarly during the walk test in both
groups then plateaued. This suggests that increases in lung
hyperinflation occur early during walk test exercise.Dyspnea and leg fatigue responses were also similar in both
groups. Therefore, quite remarkably, the physiologic
responses during the 6 min walk test appear to be similar in
obese and non-obese COPD patients.
Our results from the 6 min walk test are very similar to
those from a study of 20 COPD patients (BMI Z 28 kg/m2,
FEV1 Z 45%) by Troosters and colleagues,20 who showed
a plateau in VO2 beginning at the 3rd minute and VE
beginning at the 4th minute of walking. As the authors
indicate, a steady-state VO2 appears to be a distinct
feature of the 6 min walk test in COPD. The VE at the end of
the 6 min walk in the Troosters study averaged 91% of the
MVV, indicating substantial ventilatory limitation to this
exercise. In contrast the VE/MVV at the end of the 6 min
walk in our study was less than 50% in both groups. The
reason(s) for this discrepancy are unclear, but it may relate
to methodological issues (we estimated MVV from the FEV1)
or differences in COPD in the two populations.
Peak VO2, expressed as L/min, at the end of the 6 min
walk test tended to be higher in the obese COPD group, but
differences were not significant. This probably reflects the
small number of subjects in our study. Indeed, our study
results contrast with those of Ora and colleagues.20 and
Laviolette and colleagues21 who demonstrated that obese
COPD patients had higher peak symptom-limited oxygen
uptake than non-obese patients. The authors from the
former study suggested this increased performance was
related to less resting lung hyperinflation.
In summary, obese COPD patients had shorter 6 min walk
distances but the total amount ofwork performed during this
test was similar to matched non-obese patients. This
suggests that, at least for functional exercise capacity, the
increased metabolic load associated with obesity offsets the
potential beneficial influence of lower resting lung volumes.
Physiologic responses during the walk test indicate the
attainment of a steady-state by the second to thirdminute of
walking. This was evidenced by VO2 and VE values at
approximately 75% of the maximal values determined during
treadmill testing. Physiologic responses of obese patients
were very similar to non-obese patients during thewalk test.
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